Does Blue Cross Blue Shield of Michigan Cover Saxenda?

How BCBSM Classifies Saxenda on Its Formulary

Blue Cross Blue Shield of Michigan places Saxenda in a non-preferred brand or specialty tier on most commercial formularies, which means higher out-of-pocket costs and mandatory prior authorization before the pharmacy can fill the prescription. The exact tier depends on your specific plan document, employer group, or individual marketplace selection.

BCBSM administers coverage through two primary entities: Blue Cross Blue Shield of Michigan (the traditional carrier) and Blue Care Network (BCN), the HMO affiliate. Both share a common pharmacy benefit manager but maintain separate formulary committees that review anti-obesity medications on an annual cycle. Saxenda has appeared on BCBSM commercial formularies since 2016, though its placement has shifted between Tier 3 and Tier 4 depending on the plan year and negotiated rebate agreements with Novo Nordisk 1.

For BCBSM Medicare Advantage members, coverage is more complicated. Original Medicare Part D excluded anti-obesity medications until the Treat and Reduce Obesity Act gained traction in Congress. As of 2025, select Medicare Advantage plans with enhanced benefits now include limited coverage for FDA-approved weight-loss drugs, but members should verify their specific Evidence of Coverage document. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for patients with a BMI of 30 or greater 2, giving prescribers a strong foundation for coverage arguments.

Medicaid plans administered through Michigan's Healthy Michigan Plan have separate rules. Most Medicaid managed-care organizations in the state do not cover Saxenda, though this policy is under active review following CMS guidance encouraging state Medicaid programs to expand anti-obesity drug access.

Prior Authorization Criteria You Need to Meet

Prior authorization is the single biggest barrier between a Saxenda prescription and a filled pharmacy order. BCBSM requires it on every plan type.

The standard BCBSM prior authorization form for Saxenda requires documentation of five items: (1) a current BMI of 30 or above, or 27 or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia; (2) confirmation that the patient is 18 years or older; (3) evidence of participation in a structured lifestyle modification program (diet plus exercise) for a minimum of 3 months within the prior 12 months; (4) prescriber attestation that the medication will be used alongside continued behavioral counseling; and (5) a plan for periodic reassessment, typically at 16 weeks, to confirm at least 4% total body weight loss 3.

That 16-week checkpoint matters. BCBSM aligns with the FDA label, which states that Saxenda should be discontinued if a patient has not lost at least 4% of baseline body weight by week 16 at the full 3.0 mg dose 4. Failure to meet this threshold gives BCBSM grounds to deny reauthorization.

Some employer-sponsored BCBSM plans also impose step therapy, requiring a documented trial of a less expensive agent (typically orlistat 120 mg or phentermine) before authorizing Saxenda. If your plan includes step therapy, ask your prescriber to document prior medication trials explicitly in the chart, including start dates, duration, and reason for discontinuation.

Dr. W. Timothy Garvey, past president of the Obesity Medicine Association, has stated: "Prior authorization for anti-obesity medications creates a treatment gap that disproportionately affects patients who have already struggled through multiple failed diet attempts. The clinical evidence supporting GLP-1 therapies is strong enough that these administrative barriers should be minimized."

What You Can Expect to Pay Out of Pocket

Even with BCBSM approval, Saxenda copays can be significant. The retail price for a 30-day supply (five 3 mL pens delivering the maintenance dose of 3.0 mg daily) is approximately $1,349 without insurance.

On a Tier 3 BCBSM commercial plan, the typical copay ranges from $150 to $300 per month. On Tier 4 or specialty plans, coinsurance of 20% to 30% applies, pushing monthly costs to $270 to $405 before reaching any out-of-pocket maximum. Patients with high-deductible health plans (HDHPs) bear the full retail cost until meeting their deductible, which averaged $3,042 for single coverage in Michigan in 2024 according to KFF employer survey data.

Novo Nordisk's Saxenda Savings Card can reduce costs to as low as $25 per month for commercially insured patients, with a maximum annual benefit of $200 per 30-day fill. This card does not apply to government-funded plans including Medicare, Medicaid, or Tricare 5.

For patients whose insurance covers Saxenda but leaves high cost-sharing, specialty pharmacies contracted with BCBSM (such as AllianceRx Walgreens Prime) may offer lower per-unit pricing than retail pharmacies. Ask your prescriber to route the prescription through BCBSM's preferred specialty pharmacy network.

A practical cost comparison: Saxenda at $1,349/month compares to semaglutide 2.4 mg (Wegovy) at approximately $1,349/month and tirzepatide (Zepbound) at approximately $1,059/month. All three carry similar insurance hurdles, but tirzepatide's lower list price and newer market position may influence formulary preference at some BCBSM employer groups.

The Clinical Evidence Behind Saxenda

Understanding why BCBSM covers Saxenda at all requires looking at the clinical data that earned its FDA approval and subsequent guideline endorsements.

The SCALE Obesity and Prediabetes trial (N=3,731) randomized adults with a BMI of 30 or above (or 27 or above with comorbidity) to liraglutide 3.0 mg or placebo for 56 weeks. The liraglutide group achieved 8.0% mean total body weight loss compared with 2.6% in the placebo group. A total of 63.2% of liraglutide-treated patients lost at least 5% of body weight, versus 27.1% on placebo 6.

The SCALE Diabetes trial (N=846) focused specifically on adults with type 2 diabetes and BMI of 27 or above. At 56 weeks, liraglutide 3.0 mg produced 6.0% mean weight loss versus 2.0% with placebo, with 54.3% of the drug group achieving the 5% threshold 7. HbA1c dropped by 1.3 percentage points with liraglutide versus 0.3 points with placebo, a finding that strengthens the case for coverage in patients with concurrent diabetes.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement on obesity management notes: "Liraglutide 3.0 mg remains a reasonable first-line pharmacotherapy option, particularly for patients with prediabetes or type 2 diabetes who may benefit from its glycemic effects alongside weight reduction" 8.

These data points are the foundation of any prior authorization or appeal letter. Reference them directly.

How to Appeal a BCBSM Denial

Denials happen. They happen frequently with anti-obesity medications. A 2023 analysis published in Obesity found that initial prior authorization denial rates for GLP-1 receptor agonists used for weight management exceeded 40% across major commercial insurers 9.

BCBSM allows a two-level internal appeal process followed by an external independent review. Here is the sequence:

Level 1 internal appeal. You or your prescriber must file within 60 days of the denial. Include the denial letter, a letter of medical necessity from the prescribing physician, relevant clinical notes documenting BMI history and prior weight-loss attempts, and citations to the SCALE trial data and AACE or Endocrine Society guidelines. Turnaround is typically 30 calendar days for standard cases and 72 hours for urgent/expedited reviews.

Level 2 internal appeal. If Level 1 fails, a second appeal goes to a different reviewer within BCBSM. Submit any new clinical information gathered since the first appeal, such as worsening comorbidities or additional specialist letters.

External review. After exhausting both internal levels, Michigan law (MCL 550.1913) allows you to request an independent external review through the Michigan Department of Insurance and Financial Services (DIFS). An independent review organization (IRO) with clinical expertise in obesity medicine evaluates the case. The IRO's decision is binding on BCBSM.

Three practical tips for a stronger appeal: First, have the prescriber use ICD-10 code E66.01 (morbid obesity due to excess calories) rather than the vague E66.9 (obesity, unspecified), because specific coding reduces administrative friction. Second, include a peer-reviewed reference list. Third, if the patient has obstructive sleep apnea, osteoarthritis, or NAFLD/MASLD attributable to excess weight, document each condition with recent labs or imaging, because comorbidity burden strengthens the medical necessity argument.

Saxenda vs. Other GLP-1 Options on BCBSM Formularies

BCBSM's formulary does not treat all GLP-1 receptor agonists equally. Coverage rules vary by indication (weight management vs. type 2 diabetes), and switching between agents may require a new prior authorization.

Saxenda (liraglutide 3.0 mg) is FDA-approved only for chronic weight management. It is distinct from Victoza (liraglutide 1.8 mg), which is approved for type 2 diabetes. BCBSM treats these as separate formulary entries with different PA criteria. Writing a prescription for Victoza at the 1.8 mg dose "for weight loss" is off-label and will typically be denied.

Wegovy (semaglutide 2.4 mg) has largely replaced Saxenda as the preferred GLP-1 for weight management on several BCBSM employer plans, driven by the STEP-1 trial (N=1,961) showing 14.9% mean weight loss at 68 weeks versus 2.4% with placebo 10. Where BCBSM prefers Wegovy, Saxenda may require a step-through-failure or non-formulary exception request.

Zepbound (tirzepatide), the dual GIP/GLP-1 receptor agonist, earned FDA approval for chronic weight management in November 2023. The SURMOUNT-1 trial (N=2,539) demonstrated 20.9% mean weight loss with tirzepatide 15 mg at 72 weeks versus 3.1% with placebo 11. Some BCBSM plans now include Zepbound as a preferred agent, which may push Saxenda further down the formulary hierarchy.

For patients who specifically need Saxenda (perhaps due to tolerability issues with weekly injectables or prescriber preference for the daily dosing schedule), the prescriber should document the clinical rationale for choosing liraglutide over semaglutide or tirzepatide. This documentation prevents the insurer from redirecting the patient to an alternative without clinical justification.

Special Populations and Coverage Considerations

Certain patient populations face unique coverage dynamics with BCBSM and Saxenda.

Adolescents (ages 12 to 17). The FDA expanded Saxenda's approval to adolescents aged 12 and older with obesity (BMI at or above the 95th percentile for age and sex) in December 2020, based on a 56-week randomized trial (N=251) showing liraglutide 3.0 mg produced a 2.65% reduction in BMI compared with a 1.63% increase with placebo 12. BCBSM commercial plans that cover Saxenda for adults generally extend coverage to FDA-eligible adolescents, but the prior authorization criteria are stricter, typically requiring documentation from a pediatric endocrinologist or obesity medicine specialist.

Post-bariatric surgery patients. Some BCBSM plans exclude anti-obesity medications for patients who have already undergone bariatric surgery, reasoning that pharmacotherapy is redundant. This exclusion is medically questionable. A 2022 systematic review in Obesity Surgery found that GLP-1 agonists produced an additional 6.5% to 10.2% weight loss in post-bariatric patients with weight regain 13. If your plan contains this exclusion, an appeal citing the post-surgical regain literature may succeed.

Patients with prediabetes. The SCALE Obesity and Prediabetes trial showed liraglutide 3.0 mg reduced the risk of developing type 2 diabetes by 79% over 56 weeks compared with placebo among participants with prediabetes at baseline 6. This prevention angle adds weight to medical necessity arguments, particularly for BCBSM plans that cover diabetes prevention programs.

Practical Steps to Get Saxenda Covered Today

Start with a call to BCBSM member services at the number on the back of your insurance card. Ask three specific questions: (1) Is Saxenda on my plan's formulary? (2) What tier is it on? (3) What are the prior authorization requirements and any step therapy obligations?

Next, schedule an appointment with your prescriber and bring documentation of prior weight-loss attempts, including dates, programs used, and outcomes. If you have completed a registered dietitian program, a supervised medical weight-loss program, or a structured commercial program with clinical oversight, bring records.

Your prescriber's office should submit the prior authorization electronically through BCBSM's e-PA portal (CoverMyMeds or SureScripts). Electronic submissions are processed faster than fax, typically within 48 to 72 hours for non-urgent requests.

If approved, fill the prescription through BCBSM's preferred specialty pharmacy to minimize cost. Apply the Novo Nordisk savings card if you are commercially insured. Begin the 5-week dose escalation (0.6 mg for week 1 to 1.2 mg for week 2 to 1.8 mg for week 3 to 2.4 mg for week 4, then 3.0 mg maintenance) and schedule a 16-week follow-up to document weight-loss progress for reauthorization.

If denied, file the Level 1 appeal within 14 days (not the full 60-day window) to avoid gaps in treatment. Speed matters when a patient is motivated and clinically ready.